- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Outcome of the Board Meeting revealed that Mankind Pharma Limited is progressing well post its substantial acquisition of Bharat Serums and Vaccines Limited (BSV), for which the purchase consideration is set at INR 13,790.89 Crores. The unaudited pro forma consolidated financial statements indicate significant financial positioning changes with assets now totaled at approximately INR 27,053.57 Crores.
For the six months ending September 30, 2024, the revenue from operations has reached INR 6,807.50 Crores, contributing to a profit of INR 688.80 Crores post-tax. The total financial commitments arising from this acquisition signal strategic expansion and potential market leadership in their sector, sparking a positive outlook for future growth.
The management has emphasized its intent to leverage BSV’s capabilities to enhance profit margins and operational efficiencies. Observers are encouraged to watch closely as these developments could substantially alter Mankind's competitive stance in the pharmaceutical landscape.